Equities Analysts Offer Predictions for PRAX Q3 Earnings

Key Points

• Lifesci Capital predicts that Praxis Precision Medicines will report Q3 earnings of ($3.57) per share, with full-year estimates at ($10.22) EPS.
• Praxis recently beat earnings estimates by reporting ($3.31) EPS for the last quarter, exceeding the consensus estimate of ($3.40) by $0.09.
• The stock currently holds a "Moderate Buy" rating from analysts, with a consensus price target of $85.88 and various target prices from $80.00 to $115.00 set by multiple firms.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Equities research analysts at Lifesci Capital issued their Q3 2025 EPS estimates for Praxis Precision Medicines in a report released on Wednesday, September 3rd. Lifesci Capital analyst F. Brisebois anticipates that the company will earn ($3.57) per share for the quarter. Lifesci Capital has a "Strong-Buy" rating on the stock. The consensus estimate for Praxis Precision Medicines' current full-year earnings is ($10.22) per share. Lifesci Capital also issued estimates for Praxis Precision Medicines' Q4 2025 earnings at ($3.26) EPS, FY2025 earnings at ($13.42) EPS, Q1 2026 earnings at ($3.41) EPS, Q2 2026 earnings at ($3.07) EPS, Q3 2026 earnings at ($3.40) EPS, Q4 2026 earnings at ($3.39) EPS and FY2026 earnings at ($13.26) EPS.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($3.31) EPS for the quarter, beating the consensus estimate of ($3.40) by $0.09. Praxis Precision Medicines had a negative net margin of 2,137.48% and a negative return on equity of 60.07%.

A number of other brokerages have also recently weighed in on PRAX. Oppenheimer boosted their price objective on Praxis Precision Medicines from $97.00 to $115.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Chardan Capital reaffirmed a "buy" rating and issued a $80.00 target price on shares of Praxis Precision Medicines in a report on Tuesday, July 29th. HC Wainwright reaffirmed a "buy" rating and issued a $115.00 target price (up from $105.00) on shares of Praxis Precision Medicines in a report on Tuesday, August 5th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Praxis Precision Medicines in a report on Tuesday, September 2nd. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $80.00 target price on shares of Praxis Precision Medicines in a report on Thursday, June 12th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $85.88.

Praxis Precision Medicines Stock Down 1.5%

Praxis Precision Medicines stock traded down $0.59 during mid-day trading on Friday, hitting $39.45. The company had a trading volume of 81,366 shares, compared to its average volume of 450,175. Praxis Precision Medicines has a 1 year low of $26.70 and a 1 year high of $91.83. The business has a fifty day moving average of $49.37 and a 200 day moving average of $42.64. The stock has a market cap of $830.16 million, a price-to-earnings ratio of -3.19 and a beta of 2.61.

Institutional Trading of Praxis Precision Medicines

A number of institutional investors have recently modified their holdings of PRAX. Adage Capital Partners GP L.L.C. raised its holdings in Praxis Precision Medicines by 13.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 1,974,585 shares of the company's stock worth $83,031,000 after purchasing an additional 231,827 shares during the last quarter. Cormorant Asset Management LP increased its position in shares of Praxis Precision Medicines by 3.1% in the first quarter. Cormorant Asset Management LP now owns 1,745,000 shares of the company's stock valued at $66,083,000 after buying an additional 51,781 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Praxis Precision Medicines by 2.2% in the first quarter. Vanguard Group Inc. now owns 1,087,020 shares of the company's stock valued at $41,165,000 after buying an additional 23,381 shares in the last quarter. VR Adviser LLC increased its position in shares of Praxis Precision Medicines by 40.2% in the fourth quarter. VR Adviser LLC now owns 989,985 shares of the company's stock valued at $76,189,000 after buying an additional 283,854 shares in the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of Praxis Precision Medicines by 77.5% in the fourth quarter. Janus Henderson Group PLC now owns 929,523 shares of the company's stock valued at $71,621,000 after buying an additional 405,957 shares in the last quarter. 67.84% of the stock is currently owned by hedge funds and other institutional investors.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.